BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19302924)

  • 1. A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro.
    Krishnan-Natesan S; Manavathu EK; Alangaden GJ; Chandrasekar PH
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):361-4. PubMed ID: 19302924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
    Spreghini E; Orlando F; Giannini D; Barchiesi F
    J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
    Simitsopoulou M; Roilides E; Maloukou A; Gil-Lamaignere C; Walsh TJ
    Mycoses; 2008 Mar; 51(2):147-54. PubMed ID: 18254752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermia sensitizes Rhizopus oryzae to posaconazole and itraconazole action through apoptosis.
    Shirazi F; Pontikos MA; Walsh TJ; Albert N; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4360-8. PubMed ID: 23817366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
    Dannaoui E; Meis JF; Loebenberg D; Verweij PE
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3647-50. PubMed ID: 14576138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of phenothiazines and their combinations with amphotericin B against Zygomycetes causing rhinocerebral zygomycosis.
    Galgóczy L; Papp T; Kovács L; Ordögh L; Vágvölgyi C
    Med Mycol; 2009 May; 47(3):331-5. PubMed ID: 18798117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole prophylaxis in experimental systemic zygomycosis.
    Barchiesi F; Spreghini E; Santinelli A; Fothergill AW; Pisa E; Giannini D; Rinaldi MG; Scalise G
    Antimicrob Agents Chemother; 2007 Jan; 51(1):73-7. PubMed ID: 17060525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology.
    Szabo Z; Borbely A; Kardos G; Somogyvari F; Kemény-Beke A; Asztalos L; Rozgonyi F; Majoros L
    Mycoses; 2010 May; 53(3):196-9. PubMed ID: 19761489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.
    Lignell A; Löwdin E; Cars O; Sjölin J
    J Antimicrob Chemother; 2008 Jul; 62(1):142-8. PubMed ID: 18408237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of Amphotericin B against zygomycetes isolated from deep mycoses: a comparative study between incubation in aerobic and hyperbaric atmosphere.
    Farina C; Marchesi G; Passera M; Diliberto C; Russello G; Favalli A
    Med Mycol; 2012 May; 50(4):427-32. PubMed ID: 21954953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.
    Torres-Narbona M; Guinea J; Martínez-Alarcón J; Peláez T; Bouza E
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1126-9. PubMed ID: 17194821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.
    Espinel-Ingroff A
    J Clin Microbiol; 2006 Oct; 44(10):3616-22. PubMed ID: 16943356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of SPA-S-843 in vitro activity against filamentous fungi.
    Rimaroli C; Bruzzese T
    Chemotherapy; 2000; 46(1):28-35. PubMed ID: 10601795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes.
    Galgóczy L; Lukács G; Nyilasi I; Papp T; Vágvölgyi C
    Acta Biol Hung; 2010 Sep; 61(3):356-65. PubMed ID: 20724281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of posaconazole against clinical isolates of dermatophytes.
    Barchiesi F; Arzeni D; Camiletti V; Simonetti O; Cellini A; Offidani AM; Scalise G
    J Clin Microbiol; 2001 Nov; 39(11):4208-9. PubMed ID: 11682563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.